Related Experiment Video
Updated: Jan 22, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines
Junya Iwasaki1,2, Toshiharu Komori1, Fumio Nakagawa1
1Applied Pharmacology Section, Pharmacology Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.
Background/Aim:
Trabectedin is a DNA-damaging agent and has been approved for the treatment of patients with advanced soft tissue sarcoma. Schlafen 11 (SLFN11) was identified as a dominant determinant of the response to DNA-damaging agents. The aim of the study was to clarify the association between SLFN11 expression and the antitumor activity of trabectedin.
Materials And Methods:
The antitumor activity of trabectedin was evaluated under different expression levels of SLFN11 regulated by RNA interference and CRISPR-Cas9 systems, and the combined antitumor activity of ataxia telangiectasia and Rad3-related protein kinase (ATR) inhibitor and trabectedin in sarcoma cell lines using in vitro a cell viability assay and in vivo xenograft models.
Results:
SLFN11-knockdown cell lines had a lower sensitivity to trabectedin, compared to parental cells. ATR inhibitor enhanced the antitumor activity of trabectedin in SLFN11-knockdown cells and in a SLFN11-knockout xenograft model.
Conclusion:
SLFN11 expression might be a key factor in the antitumor activity of trabectedin.
Insights
Schlafen 11 (SLFN11) expression levels influence trabectedin
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Trabectedin is an approved DNA-damaging agent for advanced soft tissue sarcoma.
- Schlafen 11 (SLFN11) is a key determinant of response to DNA-damaging agents.
Purpose of the Study:
- To investigate the association between SLFN11 expression and trabectedin's antitumor activity.
- To explore combination therapy with ATR inhibitors.
Main Methods:
- Evaluated trabectedin's antitumor activity in cell lines with varying SLFN11 expression (RNA interference, CRISPR-Cas9).
- Assessed combination therapy of ATR inhibitor and trabectedin in vitro and in vivo xenograft models.
Main Results:
- SLFN11 knockdown reduced sensitivity to trabectedin.
- ATR inhibitor enhanced trabectedin's activity in SLFN11-low/knockout models.
Conclusions:
- SLFN11 expression is a critical factor in trabectedin's efficacy.
- Combination with ATR inhibitors may overcome resistance.
Related Concept Videos
Cell Lines
Cell Specific Gene Expression
Cell Specific Gene Expression
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Lossless Lines
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...

